Testing a new medication for advanced liver disease from bile duct damage

Plain-English translation of NCT06051617 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Read our Primary Biliary Cholangitis research guide →

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing a medication called to see if it can help people whose livers are scarred (cirrhosis) from a disease called primary biliary cholangitis. The study will compare to a placebo (a pill with no active medicine) to understand whether the medication can improve how people with this advanced liver disease feel and what happens to their health over time.

Primary biliary cholangitis is a progressive disease where the immune system damages bile ducts in the liver, eventually leading to scarring and cirrhosis. There is a need for new treatments that can slow or stop liver damage and improve outcomes for patients whose disease has already advanced to this stage.

Do you qualify?

You likely qualify if…

you are at least 18 years old
you have been diagnosed with primary biliary cholangitis
you have evidence of cirrhosis (scarring of the liver)
your liver disease is still compensated, meaning your liver can still do most of its job (rated as Child-Pugh A or B)
you are willing to use effective birth control during the study and for 90 days after

You likely don't qualify if…

you have previously taken seladelpar
you have had a liver transplant or are currently waiting for one
your cirrhosis is decompensated (meaning your liver is failing and cannot do its job properly)
you have been hospitalized for liver-related complications in the past 12 weeks
you have blood clots in the veins of your liver or very abnormal liver blood tests

What participation looks like

If you join this study, you will be randomly assigned to receive either or a placebo pill, and neither you nor your doctor will know which one you're taking at first (this is called double-blinded). You will visit the research clinic regularly for blood tests, physical exams, and assessments to track how your liver is doing. The study will follow you over time to see whether the medication helps prevent liver complications and improves your health.

AI-generated summary from trial data · Jul 2, 2026 · Not medical advice

Trial locations(205 sites)

United States

University of Alabama at Birmingham, Birmingham, Alabama

St. Joseph's Hospital and Medical Center - 350 W. Thomas, Phoenix, Arizona

OM Research LLC, Lancaster, California

SCPMG/Kaiser Permanente Los Angeles Medical Center, Los Angeles, California

Cedar Sinai Medical Center, Los Angeles, California